Memorial Sloan Kettering Cancer Center

CHICAGO — Trastuzumab deruxtecan significantly extended PFS and OS among patients with HER2-low metastatic breast cancer, regardless of hormone receptor status, compared with standard of care therapy.

CHICAGO — A single infusion of letetresgene autoleucel demonstrated antitumor activity among patients with advanced or metastatic myxoid/round cell liposarcoma, results from a pilot study suggested.

Despite a high upfront price, treatment with axicabtagene ciloleucel appeared more cost-effective as second-line therapy than standard treatment for relapsed or refractory large B-cell lymphoma, according to study results.

The addition of utomilumab after infusion with axicabtagene ciloleucel induced a 75% response rate among adults with relapsed or refractory large B-cell lymphoma, data from the ZUMA-11 trial showed.

Break Through Cancer will award $50 million in grants designed to maximize interdisciplinary collaboration among researchers at five top cancer centers.

In this video, Debu Tripathy, MD, discussed the role of oral selective estrogen receptor down regulators in treating breast cancer patients with ESR1 mutations.

Younger patients with acute lymphoblastic leukemia who do not respond to CD19-directed chimeric antigen receptor T-cell therapy exhibit certain gene regulation patterns that may be associated with treatment resistance, study results show.

Sotorasib exhibited durable efficacy among certain adults with locally advanced or metastatic non-small cell lung cancer, according to study results presented at American Association for Cancer Research Annual Meeting.

The FDA’s approval of tisagenlecleucel in 2017 resulted in an explosion of research into chimeric antigen receptor T-cell therapies.

RFS is not an adequate surrogate for OS among patients who undergo resection for colorectal liver metastases, according to study results presented at Society of Surgical Oncology 2022 International Conference on Surgical Cancer Care.